Neoadjuvant Therapy of Pancreatic Cancer
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (15 January 2024) | Viewed by 434
Special Issue Editors
Interests: hepato-pancreatobiliary cancer; systemic therapy; precision medicine
Special Issues, Collections and Topics in MDPI journals
Interests: multimodality therapy; neoadjuvant therapy; gastrointestinal and hepatopancreatobiliary cancers; neuroendocrine tumors; surgery; patient-centered outcomes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pancreatic cancer is predicted to become the second leading cause of cancer-related death by 2030. As such, and despite advancements in outcome in the past decade, it is necessary to further increase our understanding of this fatal disease.
We are pleased to invite you to contribute to the Special Issue on research refining guidance of patients in the neoadjuvant trajectory for pancreatic cancer. We include basic, translational, and clinical studies regarding neoadjuvant therapy, focusing on predictive and prognostic markers to oppose futile surgery and improve outcome. Furthermore, this Special Issue aims to sharpen therapeutic neoadjuvant strategies, including cutting-edge systemic targets and precision medicine.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) neoadjuvant treatments and supportive strategies to conquer invalidating toxic events and augment patients’ body composition. In addition to pancreatic cancer, research on overarching periampullary cancers will be considered.
We look forward to receiving your contributions.
You may choose our Joint Special Issue in Cancers.
Dr. Judith De Vos-Geelen
Dr. Jordan M. Cloyd
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- preoperative
- neoadjuvant
- systemic therapy
- prognostic biomarkers
- predictive biomarkers
- physical activity
- body composition
- toxicity
- quality of life
